Update on TNF Inhibitors | Zendy

Francisco A. Kerdel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Update on TNF Inhibitors

Author(s) -

Francisco A. Kerdel

Publication year - 2016

Publication title -

seminars in cutaneous medicine and surgery

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 0.66

H-Index - 64

eISSN - 1558-0768

pISSN - 1085-5629

DOI - 10.12788/j.sder.2016.019

Subject(s) - medicine , etanercept , tumor necrosis factor alpha , psoriasis , tumor necrosis factor α , adalimumab , intensive care medicine , infliximab , pharmacology , dermatology

The introduction of tumor necrosis factor (TNF)-α inhibitors dramatically improved the management of psoriasis. Some newer or investigational biologics with different mechanisms of action have demonstrated noninferiority or superiority to etanercept, the first self-injectable anti-TNF-α agent to become available in the United States. Nonetheless, TNF-α inhibitors are likely to remain a mainstay of therapy for many years.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research